Atlas Trials

Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia

Clinical trial NCT07735104 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07735104
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Cancer Cachexia SyndromeCancer Cachexia
Start date
2026-09-01
Primary completion
2028-10-30
Enrollment
88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.